Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jonathan E Rosenberg

Showing results (1-10 of 271) with videos related to

Pageof 28
Sort By:
Expert Review of Anticancer Therapy|December 8, 2007
Current status of neoadjuvant and adjuvant chemotherapy for muscle-invasive bladder cancerJonathan E Rosenberg
Clinical Advances in Hematology & Oncology : H&O|March 19, 2021
New treatments for patients with progressive metastatic urothelial carcinomaJonathan E Rosenberg
Expert Review of Anticancer Therapy|June 20, 2020
The emerging role of antibody-drug conjugates in urothelial carcinomaMichael Lattanzi, Jonathan E Rosenberg
Future Oncology (London, England)|March 25, 2025
Enfortumab vedotin and pembrolizumab: redefining the standard of care for previously untreated advanced urothelial cancerMichal Sternschuss, Jonathan E Rosenberg
Drug Design, Development and Therapy|February 1, 2012
Abiraterone acetate: oral androgen biosynthesis inhibitor for treatment of castration-resistant prostate cancerYasser Rehman, Jonathan E Rosenberg
Current Oncology Reports|February 3, 2020
Antibody-Drug Conjugates in Urothelial CarcinomasMichal Sarfaty, Jonathan E Rosenberg
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 28, 2019
Reply to F.E. Vera-Badillo et alJonathan E Rosenberg, Daniel P Petrylak
Expert Opinion on Biological Therapy|May 25, 2021
Targeting nectin-4 by antibody-drug conjugates for the treatment of urothelial carcinomaJeffrey L Wong, Jonathan E Rosenberg
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 20, 2021
<i>NECTIN4</i> Heterogeneity and Molecular Diversity in Bladder Cancers: Deconstructing the Activity of An Antibody-Drug ConjugateMin Yuen Teo, Jonathan E Rosenberg
Expert Review of Anticancer Therapy|January 25, 2018
Nivolumab for the treatment of urothelial cancersMin Yuen Teo, Jonathan E Rosenberg
Pageof 28

Showing results (1-10 of 271) with videos related to

Sort By:
Pageof 28
Expert Review of Anticancer Therapy|December 8, 2007
Current status of neoadjuvant and adjuvant chemotherapy for muscle-invasive bladder cancerJonathan E Rosenberg
Clinical Advances in Hematology & Oncology : H&O|March 19, 2021
New treatments for patients with progressive metastatic urothelial carcinomaJonathan E Rosenberg
Expert Review of Anticancer Therapy|June 20, 2020
The emerging role of antibody-drug conjugates in urothelial carcinomaMichael Lattanzi, Jonathan E Rosenberg
Future Oncology (London, England)|March 25, 2025
Enfortumab vedotin and pembrolizumab: redefining the standard of care for previously untreated advanced urothelial cancerMichal Sternschuss, Jonathan E Rosenberg
Drug Design, Development and Therapy|February 1, 2012
Abiraterone acetate: oral androgen biosynthesis inhibitor for treatment of castration-resistant prostate cancerYasser Rehman, Jonathan E Rosenberg
Current Oncology Reports|February 3, 2020
Antibody-Drug Conjugates in Urothelial CarcinomasMichal Sarfaty, Jonathan E Rosenberg
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 28, 2019
Reply to F.E. Vera-Badillo et alJonathan E Rosenberg, Daniel P Petrylak
Expert Opinion on Biological Therapy|May 25, 2021
Targeting nectin-4 by antibody-drug conjugates for the treatment of urothelial carcinomaJeffrey L Wong, Jonathan E Rosenberg
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 20, 2021
<i>NECTIN4</i> Heterogeneity and Molecular Diversity in Bladder Cancers: Deconstructing the Activity of An Antibody-Drug ConjugateMin Yuen Teo, Jonathan E Rosenberg
Expert Review of Anticancer Therapy|January 25, 2018
Nivolumab for the treatment of urothelial cancersMin Yuen Teo, Jonathan E Rosenberg
Pageof 28